Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493247 | 0.82 | MAPT (0.56) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL3063033 | 0.74 | SIRT6 (0.59) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL2884326 | 0.74 | SIRT6 (0.48) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL29581173 | 0.73 | MEN1 (0.48) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL5266222 | 0.73 | HRH3 (0.45) | ALDH1A1POLBHSD17B10 | |
| SCHEMBL6719932 | 0.72 | HRH3 (0.56) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL2537629 | 0.72 | POLB (0.49) | SIRT6MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL8448356 | 0.72 | HRH3 (0.56) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL15828757 | 0.72 | MAPT (0.49) | SIRT6LMNAMAPTMEN1KMT2A | |
| SCHEMBL5264181 | 0.71 | SIRT6 (0.46) | SIRT6LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586609-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7838547-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| CN-101006091-B | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI AVENTIS DEUTSCHLAND | 2010-09-15 | — | — | CN | disclosed |
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| CN-101006091-A | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-07-25 | — | — | CN | disclosed |
| EP-1781663-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018280-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | SIRT6 1637/4885LMNA 1708/4885MAPT 2703/4885 |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | SIRT6 1637/4885LMNA 1708/4885MAPT 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.